Niraparib for the treatment of metastatic ccRCC in a patient with CDK12 and RAD51C mutations: a case report
X Yue, C Yang, D Cao, Y Li - Frontiers in Pharmacology, 2024 - frontiersin.org
Background Niraparib, a poly ADP-ribose polymerase inhibitors (PARPi), has been widely
applied in the intervention of epithelial ovarian, fallopian tube, or primary peritoneal cancer …
applied in the intervention of epithelial ovarian, fallopian tube, or primary peritoneal cancer …